Defense Advanced Research Projects Agency (DARPA) has awarded a $6.8m contract to Aethlon Medical to develop a therapeutic device to reduce the incidence of sepsis.

The contract programme will leverage the Aethlon ADAPT system as a core technology component underlying an extracorporeal blood purification device which selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Aethlon ADAPT system is an adaptive dialysis-like affinity platform technology that selectively targets the clearance of harmful agents from the circulatory system without the loss of essential blood components.

The ADAPT system, which is being developed under DARPA’s dialysis like therapeutics (DLT) programme, is expected to decrease the morbidity and mortality of sepsis.

Aethlon Medical chairman and CEO Jim Joyce said the award reinforces the expansive capabilities of ADAPT system, increases the breadth of their product pipeline and transitions them from a development-stage to revenue-stage organisation.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now